Search

We regularly make applications for grants to fund our information and support projects and have recently been successful in securing £12,000 from The National Lottery Community Fund.

• News

A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.

• News
• Retinitis pigmentosa

My name is Mark Baxter and from an early age I was diagnosed with a deteriorating retinal eye condition called retinitis pigmentosa or RP for short, which will slowly lead to blindness.

• Case study - community
• Written

Biotechnology company ProQR has announced that its clinical trials of sepofarsen for Leber congenital amaurosis type 10 and ultevursen for USH2A-mediated retinitis pigmentosa will be wound down with immediate effect.

• News

Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.

• News
• Stargardt disease

Aged 20, James was diagnosed with retinitis pigmentosa at a routine eye appointment in September 2015 and registered partially sighted, just prior to buying his first car and taking his driving test.

• Case study - community
• Written

Rachael first noticed she had sight problems at the age of 15. She went to her local eye clinic, who said she had an astigmatism.

• Case study - community
• Written

Giving a regular monthly or quarterly donation of any amount is a wonderful way to help Retina UK support the inherited sight loss community.

These frequently asked questions should provide a response for most of the queries you might raise.

Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.

• News
• Leber congenital amaurosis (LCA)